Clearside Biomedical, Inc. (CLSD) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 8.41
30Y Low1.4·High14.5
ROE
↑
N/A
—
5yr avg: -105.6%
30Y Low-368%·High2%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLSD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Clearside Biomedical, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $70M | $72M | $67M | $165M | $127M | $111M | $33M | $177M | $117M | — |
| Enterprise Value | $35M | $103M | $86M | $54M | $135M | $112M | $95M | $35M | $176M | $90M | — |
| P/E Ratio → | -0.06 | — | — | — | 436.51 | — | — | — | — | — | — |
| P/S Ratio | 1.29 | 42.14 | 8.79 | 50.81 | 5.57 | 16.14 | 50.94 | 1096.17 | 513.57 | 225.41 | — |
| P/B Ratio | — | — | — | 6.36 | 4.34 | 14.54 | 9.92 | 1.39 | 8.27 | 1.64 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CLSD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 61.64 | 10.50 | 40.90 | 4.56 | 14.20 | 43.49 | 1160.57 | 510.05 | 173.03 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 359.00 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CLSD Profitability
Margins and return-on-capital ratios measuring operating efficiency
Clearside Biomedical, Inc. earns an operating margin of -1735.7%. Operating margins have expanded from -2281.6% to -1735.7% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.0% | 91.0% | 95.7% | 84.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -1735.7% | -1735.7% | -302.0% | -2281.6% | -2.1% | -227.2% | -1394.6% | -276483.3% | -16929.9% | -4845.8% | — |
| Net Profit Margin | -2064.4% | -2064.4% | -394.9% | -2482.8% | 1.3% | -230.7% | -1416.0% | -276060.0% | -17094.2% | -4977.3% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -135.6% | 1.6% | -182.8% | -177.0% | -367.8% | -126.7% | -147.9% | — |
| ROA | -116.2% | -116.2% | -76.1% | -69.9% | 1.2% | -79.0% | -86.8% | -195.8% | -94.1% | -48.9% | -112.5% |
| ROIC | — | — | — | -801.7% | -56.3% | — | -221.5% | -271.9% | -135.6% | -42.5% | — |
| ROCE | -121.5% | -121.5% | -68.3% | -72.3% | -2.6% | -142.0% | -122.4% | -273.7% | -109.8% | -52.9% | -145.9% |
CLSD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $32M ($52M total debt minus $20M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 3.32 | 0.02 | 0.23 | 0.57 | 0.42 | 0.37 | 0.11 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -1.24 | -0.78 | -1.75 | -1.45 | 0.08 | -0.06 | -0.38 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.95 | -2.95 | -2.65 | -9.07 | — | -53.54 | -29.31 | — | — | — | -52.48 |
CLSD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Clearside Biomedical, Inc.'s current ratio of 4.44x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 8.54x to 4.44x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.44 | 4.44 | 4.42 | 8.54 | 9.08 | 1.82 | 2.31 | 4.10 | 2.78 | 15.46 | 3.94 |
| Quick Ratio | 4.44 | 4.44 | 4.42 | 8.54 | 8.88 | 1.82 | 2.31 | 4.10 | 2.78 | 15.46 | 3.94 |
| Cash Ratio | 4.18 | 4.18 | 4.24 | 8.37 | 6.56 | 1.74 | 2.07 | 3.90 | 2.78 | 15.46 | 3.90 |
| Asset Turnover | — | 0.07 | 0.24 | 0.03 | 0.69 | 0.41 | 0.08 | 0.00 | 0.01 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 111.21 | 7.54 | — | 123.42 | — | — | — | — | — | — |
CLSD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Clearside Biomedical, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 0.2% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $5M | $4M | $4M | $4M | $3M | $3M | $2M | $2M | $874071 | $818302 |
Peer Comparison
Compare CLSD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLSDYou | $2M | -0.1 | — | — | 91.0% | -1735.7% | — | — | — |
 OCUL | $2B | -6.8 | — | — | 87.3% | -521.0% | -54.9% | — | — |
 ADVM | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 EW | $48B | 45.2 | 25.4 | 35.7 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See CLSD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLSD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLSD vs OCUL
Side-by-side business, growth, and profitability comparison vs Ocular Therapeutix, Inc..
Start ComparisonCLSD — Frequently Asked Questions
Quick answers to the most common questions about buying CLSD stock.
What is Clearside Biomedical, Inc.'s P/E ratio?
Clearside Biomedical, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Is CLSD stock overvalued?
Based on historical data, Clearside Biomedical, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Clearside Biomedical, Inc.'s profit margins?
Clearside Biomedical, Inc. has 91.0% gross margin and -1735.7% operating margin.